PTC Therapeutics Inc.
PTC Therapeutics develops and markets rare‑disease drugs—Translarna, Emflaza, Tegsedi, Waylivra, Evrysdi—and gene‑therapy Upstaza. Its pipeline includes PTC518 for Huntington’s disease and Sepiapterin for phenylketonuria. Partners with Roche, Novartis, and Akcea.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Hospitals and Health Care
- Industry: Medical Practices
- Employees: 939
- HQ: Warren
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.